Navigation Links
Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Date:2/27/2008

>Bystolic (nebivolol) is a novel beta blocker that was approved by the FDA in December 2007 and is approved and marketed in more than 65 countries outside of North America. Mylan licensed the U.S. and Canadian rights to Bystolic from Janssen Pharmaceutical N.V. in 2001, and obtained Janssen's consent to sub-license Bystolic to Forest Laboratories in those territories in an initial agreement completed in January 2006. Bystolic is a cardio-selective beta-1 blocker, with vasodilation properties and a favorable tolerability profile. Upon FDA approval, Bystolic has received five years of marketing exclusivity under the Hatch Waxman legislation. In addition there is an issued U.S. pharmaceutical composition of matter patent that expires in 2021, which may offer additional exclusivity.

About Mylan

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform act of 1995, including with regard to the future value of the product and the anticipated economic impact of the transaction. These statements involve a number of risks and uncertainties, including regulatory matters outside of the companies' contr
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... to Optimize the Management of Pain”. , The ... Medscape.com for the next year. The focus of ... to recognize inadequate pain treatments, integrate appropriate pain ...
(Date:3/4/2015)... 2015 Follow us on LinkedIn ... the fastest growing technologies in the life sciences industry. ... is driving growth in nucleic acid detection technologies like ... gene expressions will continue to benefit the qPCR and ... ranging from pharma, biotech, food & beverage to animal ...
(Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
(Date:3/3/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... control projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... volume year for bidding in 2014, we are pleased to see ... reflect the organization,s renewed focus on select market segments where we ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... RSB Spine, LLC, today announced the,first implantation of its ... was approved as an interbody device in September 2007. ... devices. In,addition, RSB Spine has recently completed the national ... cervical spine, which is being very well,received by spine ...
... AUSTIN, Texas, Jan. 16 Start Licensing, Inc.,("Start"), ... Exeter Life,Sciences supports the final risk assessment released ... 15. The assessment concluded that meat and,dairy products ... for human,consumption., "FDA,s conclusion is consistent with ...
... of Excellence, Advancing Performance in ... Patient Outcomes, Costs and Convenience, COSTA MESA, Calif., Jan. ... that it has completed the,previously announced acquisition of Neuro-Therapy Clinic, ... Daniel A. Hoffman, MD has been appointed Chief Medical Officer. ...
Cached Biology Technology:RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine 2CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 2CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 3
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/19/2015)... .19, 2015 Research and Markets ... the "Military Electro-Optical / Infrared Systems Market ... Platform - Forecast to 2020" report to ... systems market is expected to reach $16.35 billion ... This report segments the military electro-optical/infrared ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Nitrous oxide is a potent greenhouse gas and a ... the ozone. Intensively managed, grazed pastures are responsible for ... excrement. Biochar is potentially a mitigation option for reducing ... carbon can be sequestered in the soil. Biochar also ...
... 17, 2011 (BRONX, NY) Researchers at Albert ... that members of an enzyme family found in humans and ... in regulating cell motility. Their findings suggest an entirely new ... cancer. , David Sharp, Ph.D. , associate professor of ...
... now lives in cities, yet we know little about how ... kind, ecologists in Indianapolis, USA have used 70 year-old dried ... plants. The results are published this week in the British ... Dr Rebecca Dolan, director of the Friesner Herbarium, Butler University, ...
Cached Biology News:Can biochar help suppress greenhouse gases? 2Enzyme can steer cells or possibly stop them in their tracks 2Ecologists use 70-year-old pressed plants to chart city's vanishing native flora 2
... Processing of Microarrays Using the New FAST(tm) ... slide plate is designed to hold four, ... incubation chambers in a microplate footprint for ... dimensions meet the standards recommended by the ...
... pump, available in a single and twin head, ... design. With the most compact, lightweight package in ... in portable air and gas applications., Available ... T2-01TH). , Delivers 1.5 and 2.0 liters per ...
... mechanical harvesting of cells • Blade design ... with the growth surface • Designed for ... Individually wrapped • Sterilized by gamma radiation ... is a new product number, created to ...
... high-density functional protein microarray is the first ... proteinprotein interactions on a proteome scale. The ... reading frames (ORFs) expressed as 5'-GST fusions, ... 1 inch x 3 inch nitrocellulose-coated slide. ...
Biology Products: